Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Investors were keenly interested to hear an update on Amgen’s obesity drug candidates, AMG-513 and MariTide. As noted above, the FDA has put AMG-513 on a clinical hold. Amgen says that it’s in ...

Beyond these readouts, we'll be initiating several new Phase 3 trials of MariTide in obesity and related conditions. This is an exciting time for innovation in our laboratories, in our factories ...

Amgen Inc. AMGN stock is down about 1.4% in after-hours trading despite beating estimates on the top and bottom lines in its fourth quarter 2024 earnings report. Investors appear to be selling the ...

Beyond these readouts, we'll be initiating several new Phase 3 trials of MariTide in obesity and related conditions. This is an exciting time for innovation in our laboratories, in our factories with ...

That brings us to Amgen. In November, it reported mid-stage clinical trial results for MariTide, an investigational weight loss treatment, and the market responded by sending the stock down more ...